BDBM261856 5-[2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazol-5-yl]-1,3,4-oxadiazol-2(3H)-one::US9708311, 106

SMILES CCn1c2ccccc2c2cc(ccc12)-c1nc2cc(ccc2n1CCOC)-c1n[nH]c(=O)o1

InChI Key InChIKey=WJXJMRKVJIYTMN-UHFFFAOYSA-N

Data  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 261856   

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261856(5-[2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)...)
Affinity DataIC50: 43.7nMT: 2°CAssay Description:4 μl of a cAMP-d2/cell suspension (625000 cells/ml) were added to a test plate containing the substance solutions already initially introduced (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2018
Entry Details
US Patent

TargetProstaglandin E2 receptor EP4 subtype(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM261856(5-[2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)...)
Affinity DataIC50: 44nMAssay Description:Antagonist activity at human EP4R assessed as inhibition of agonist-induced cAMP production by fluorescent cAMP tracer cAMP-d2 based FRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details Article
PubMed